Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary

August 4, 2022

NASDAQ US Health Care Biotechnology earnings 50 min

Earnings Call Speaker Segments

Holly Manning

executive
#1

Thanks, operator. Hello everyone, and thanks for joining Agios' Q2 2022 earnings call this morning. Slides for today's session can be found in the Investors Section at agios.com. Joining me today with prepared remarks are our Chief Executive Officer, Dr. Jackie Fouse; Dr. Sarah Gheuens, our Chief Medical Officer and Head of Research and Development; Richard Poddar, our Chief Commercial Officer; and our Chief Financial Officer and Head of Corporate Affairs, Jonathan Biller. Before we begin, please note that certain statements made today will contain forward-looking statements. A range of risks, unknowns, and additional elements—among them the ones described in our latest SEC submissions and any subsequent filings we might submit to the SEC—could cause real outcomes and events to diverge significantly from anything suggested or stated in forward-looking remarks. Having said that, I'll now hand things over to Jackie.

Jackie Fouse

executive
#2

Appreciate that, Holly. Morning, everybody, and thank you for dialing in to our Q2 2022 earnings discussion. Across every part of our operations, the opening six months of 2022 proved incredibly fruitful. The Agios team keeps earning my admiration through their disciplined follow-through, their bonds with one another, and their dedication to our goal of changing patients' lives; back in February, our top-tier commercial group brought to market PYRUKYND, our very first genetically defined disease treatment — the initial FDA-cleared option for pyruvate kinase deficiency and the original PK activator ever to win approval. We now bring you strong commercial numbers from the first complete quarter since that launch, and Richard will walk you through those specifics. Our outstanding clinical group kicked off 2 pediatric pivotal trials in PK deficiency, plus a sickle cell disease cohort within the AG-946 Phase 1 study, while simultaneously getting the AG-946 MDS trial up and running and maintaining momentum on site activation and patient enrollment for 3 pivotal PYRUKYND studies in thalassemia and sickle cell disease; during May, we reached the difficult conclusion to restructure our research function, resulting in the continuing merger of our R&D groups and sharpening our focus on research alongside business development efforts. Then in June, we showed up strongly at the European Hematological Association Meeting in Vienna, delivering wide-ranging preclinical, translational, and clinical updates spanning the programs. Sarah will go through our preclinical and clinical programs in just a moment. For me, one standout moment came a few weeks back, when everyone at Agios gathered for our inaugural company offsite since the pandemic began 2.5 years prior. It served as a powerful reminder of just how deep the talent runs at Agios and of the tightly woven culture that keeps flourishing amid the ever-changing evolution of our business. Moving to slide 5. A few weeks back, we shared that effective Monday, August 8, I'll step into the position of Chair of the Board of Directors, with Brian Goff stepping in as Agios's incoming Chief Executive Officer. Brian brings deep expertise spanning hematology, rare diseases, and commercial and operational leadership, built across a 30-year career at worldwide biopharmaceutical firms. It's my firm conviction that he's the ideal person to steer Agios into what comes next. Looking back on my tenure as CEO, I take pride in the daring strategic choices we made together as a team, our ability to withstand a worldwide pandemic, and the individual patients whose lives we've reached via the medicines we developed. My faith in the Agios team and their capacity to deliver positive change in the world has never wavered, and that's exactly why I'm thrilled to keep contributing to that mission in my new capacity as Chair of our Board. Come Monday, my attention will be on assisting Brian in executing a seamless handover into the CEO seat, acting as a founding Board member and source of guidance, while still leaving him room to learn and chart his own decisions. I'm eager, too, to collaborate with the members of our Board as we make the most of and build upon the combined expertise we bring together, allowing us to keep serving as a strong asset for Agios and its management team while we advance toward a promising tomorrow as an organization centered on rare and genetically defined diseases. From where we stand right now, Agios enjoys a position of tremendous strength: a first-in-class commercial launch, five pivotal trials in progress, several early stage clinical studies either planned or already running, an encouraging preclinical pipeline, and a balance sheet others would envy, which offers substantial optionality for the business's future growth. It's a privilege to remain part of this remarkable team, and I'm grateful to all of you for backing Agios both now and going forward. With that, I'll hand things over to Sarah.

Sarah Gheuens

executive
#3

Appreciate that, Jackie. So, going back to May, we shared the reshaping of our research group — directing our personnel and funding toward validated preclinical efforts that already exist, and transitioning the pipeline team's approach toward in-licensing and/or picking up well-characterized, high-potential assets. That strategy let us keep a robust in-house research group dedicated to pushing our strongest internal efforts ahead, while simultaneously chasing possibilities that fit alongside our scientific know-how in cellular metabolism and our expanding clinical and commercial strengths. With that reshaping, I'm thrilled to move into my fresh position as Head of Research and Development. My priority and focus is to bring our R&D functions together smoothly, in a manner that boosts organizational coordination and efficiency and deepens how patient insights shape R&D decision-making. On slide eight, you can see we now have a completely assembled research and development organization covering every function required to propel our preclinical and clinical efforts forward, and there is a tremendous amount of talent in each of those areas. Watching how this fresh structure has already improved communication and teamwork inside the R&D organization has been genuinely rewarding. Moving to slide nine. Our research leaders are assisting us in carefully assessing the science behind and the fit of possible business development deals, and at the same time they're working diligently to push ahead our internally found preclinical efforts. As slide 10 shows, our most premature effort is a branched chain amino acids aminotransferase 2 inhibitor, referred to as BCAA2, aimed at treating propionic acidemia, called PA, and methylmalonic acidemia, also known as MMA. These acidemias form a set of inherited inborn errors of metabolism where the body is unable to break down branched-chain amino acids, which results in a toxic buildup. Blocking BCAT2 could lower the creation of these metabolites, which might allow patients to face fewer dietary and other limitations and enjoy a better quality of life. Our BCAT2 inhibitor sits in late lead optimization right now. Now to slide 11. Our furthest-along preclinical effort is the phenylalanine hydroxylate, or PAH, stabilizer aimed at treating phenylketonuria, known as PKU. PKU is an uncommon inherited lifelong condition that leads phenylalanine to build up. Bringing plasma phenylalanine concentrations to normal might let patients raise their natural protein intake, normalize their diet, and enjoy improved quality of life. This effort is nearing the development candidate milestone, and we anticipate reaching an IND next year. As slide 12 shows, over on the clinical side, we have extensive clinical development efforts for both of our PK activators, PYRUKYND and AG-946. Now to slide 13. AG-946 is our innovative PKR activator, and it's presently being assessed in a Phase 1 study featuring a healthy volunteer within a sickle cell disease component; we've finished a single ascending and multiple ascending dose healthy volunteer cohorts and are hoping to share this data at the ASH Annual Meeting later this year. We just started the sickle cell disease portion of the trial so that we can gather data on this molecule in a hemolytic anemia. Also, our belief is that activating PK could potentially enhance red blood cell health in both to intermediate myelodysplastic syndrome, or MDS, an area where there's a substantial unmet need. As you can see on slide 14, we're in the process of operationalizing the 2a portions of our AG-946 Phase 2a/2b study in MDS. The Phase 2a part of this study is an open-label proof-of-concept trial testing a single dose level of AG-946 in patients who have lower-risk MDS. Enrollment will be 20 patients, and they'll take AG-946 once a day through the 16-week core period. Those who finish the core period can then go on to an extension period. The primary endpoints are hemoglobin response, which is defined as an increase of 1.5 grams per deciliter or more from baseline in the average hemoglobin concentration from week eight through week 16, and transfusion independence, defined as being transfusion-free for eight consecutive weeks or more during the core period in patients with both transfusion burden only. Safety, additional measures of anemia, and PK and PD biomarkers make up the secondary endpoints. We're eager to get the trial started by the end of the year. Moving to slide 16 for our most advanced PK activator, mitapivat, commercially known as PYRUKYND, our clinical focus is on transforming the course of hemolytic anemia by boosting red blood cell energy, health and longevity, and we're well-positioned to become the first company to accomplish this across three distinct hemolytic anemia. As slide 16 shows, we're investigating PYRUKYND in an operationally seamless Phase 2/3 study called RISE UP in adults with sickle cell disease, aiming to be the first potential oral agents to improve anemia, reduce VOCs and improve quality of life by increasing methemoglobin, which leads to less pain and fatigue. In the Phase 2 portion, 69 patients will be randomized 1:1:1 to either 50-milligram mitapivat twice daily, 100-milligram mitapivat twice daily, or matched placebo. Hemoglobin response — defined as an increase of one gram per deciliter or more in average hemoglobin concentration from week 10 through week 12 compared to baseline — and safety are the primary endpoints. Our aim is to finish enrollment in the Phase 2 portion by the end of this year. Once the double-blind portion of Phase 2 is complete, we'll assess the totality of the data before triggering the start of Phase 3. The outcome of the primary endpoint is the first step. After that, we'll factor in changes in markers of hemolysis, the rate of sickle cell pain crisis, patient-reported septic and other secondary endpoints. If Phase 2 succeeds, these data will also let us determine the dosing paradigm for the Phase 3 portion in the protocol. Since this study runs without interruption, we can accelerate the pace of moving between one phase and the next, and we can also determine whether changes to the Phase 3 are warranted based on how Phase 2 turns out, all without affecting the trial's statistical or regulatory elements. Now for thalassemia, which is on slide 18. There's real excitement on our part about the possibility of making PYRUKYND the first oral treatment that improves hemolytic anemia and ineffective < > across data and alpha thalassemia, and also in transfusion-dependent and transfusion-independent thalassemia. Late last year, we launched our 2 worldwide placebo-controlled pivotal studies of PYRUKYND: ENERGIZE and ENERGIZE-T. To recap, ENERGIZE is set to assess 171 patients randomly assigned 2:1 to either 100 milligrams of mitapivat given twice a day or placebo, among both alpha and beta thalassemia patients who do not receive transfusions on a regular basis. The primary endpoint of hemoglobin response is defined as an increase of 1 gram per deciliter or more in average hemoglobin concentration from week 12 to week 24 relative to baseline. ENERGIZE-T is set to assess 240 patients randomly assigned 2:1 to either 100 milligrams of mitapivat given twice a day or placebo, among both alpha and beta thalassemia patients who do receive transfusions regularly, defined as six to 20 red blood cell units transfused during the 24 weeks before randomization. The primary endpoint is transfusion reduction response, defined as a 60% or greater cut in transfused red blood cell units, with a decrease of at least two units of transfused red blood cells in any consecutive 12-week period through week 48 relative to baseline. Our team is concentrating on keeping up global site activation and patient enrollment work so that a meaningful portion of patients will be enrolled in both studies by the time the year ends. Lastly, in February, PYRUKYND became the first therapy approved by the FDA for pyruvate kinase deficiency, and we are continuing our work to broaden the usefulness of this medicine to every PK deficiency patient. In June, we launched two studies of PYRUKYND in pediatric PK deficiency patients, ages one up to 18, as slide 19 shows. ACTIVATE-Kids will randomly assign 30 patients who are not regularly transfused 2:1 to either PYRUKYND or placebo and assess hemoglobin response over the 12-week course period. ACTIVATE-KidsT will randomly assign 45 regularly transfused stations 2:1 to either PYRUKYND or placebo and assess transfusion reduction over the 24-week core period. At the same time, our marketing authorization application for PYRUKYND in adult PK deficiency is still being reviewed in the EU, and we remain on schedule to get a decision from the EMA by year-end. To sum up, as slide 20 shows, we are happy with the progress achieved against our 2022 key milestones this quarter across every program. With that, I will now hand the call over to Richa, our Chief Commercial Officer.

Richa Poddar

executive
#4

Thank you, Sarah. During Q2 — the initial complete quarter following PYRUKYND's launch — our net U.S. sales came to $3.1 million. As previously mentioned, the commercial launch approach we laid out on slide 22 is designed to reach providers and help patients obtain suitable disease and product information. Our priority is making sure that, first, the roughly 1,500 to 4,000 PK deficiency patients across the U.S. get an accurate diagnosis via initiatives such as Anemia ID; second, that doctors recognize how urgently they should prescribe and advocate for eligible patients to receive treatment; and last, that patients link up with myAgios support services so they can better understand the disease, secure access, and maintain long-term medication adherence. Having completed our first full quarter, the early launch metrics encourage us, as does the meaningful feedback received from patients and physicians. I'll begin with what we consider the key metrics observed thus far, as outlined on slide 23. As of June 30, our hemolytic anemia specialists have kept engaging with customers and succeeded in driving scripts, bringing the total to 52 unique patients with completed PYRUKYND prescription enrollment forms; this has converted into 37 total patients on PYRUKYND, encompassing both new prescriptions and those continuing treatment. Importantly, this early in launch, these patients originate from a unique prescriber base of 50 physicians spread across the country, which confirms our belief that most patients are treated in the community rather than at academic medical centers or centers of excellence. The breadth of prescribing across states and practices indicates early launch health. As observed in Q1, patients starting therapy represent a range of demographics and disease characteristics highly representative of the adult PKD patient population. This includes splenectomized and non-splenectomized patients, patients regularly and not regularly transfused, young and old patients, and patients with various hemoglobin levels. Regarding payer dynamics, our national account directors keep having positive interactions with payers so far. As seen in Q1, most scripts have been approved via the medical exception process while payer policies are being developed. Payer policies are beginning to be developed, with the few now in place aligned to the indication statement or the clinical trial eligibility criteria. Moving to slide 24. We are pleased by the sustained interest in our Anemia ID kit, a free genetic testing program built to drive accurate diagnosis for patients with a general diagnosis of hemolytic anemia of unknown etiology. Over 4,200 kits have been ordered, a 20% increase since Q1. Consistent with the prior quarter, about 25% of kits have been completed, and the PK deficiency positivity rate among those completed tests remains in the mid-single-digit percentages. Among the positive tests, they are split evenly between pediatric and adult patients. Now as we move into the back part of the year, a number of items deserve attention while we keep assessing how the early launch is trending. The first thing is that per our label, patients remain on therapy for six months, and at that point a response assessment can be conducted. Drawing on what we saw in our clinical trials, we expect roughly 40% to 45% of patients to be classified as responders, judged by hemoglobin levels, markers of hemolysis, and a case-by-case evaluation of deal and function. Once we hit the six-month point in the launch, non-responding patients will begin to discontinue therapy; among those who remain on treatment, we will be in a better position to assess adherence and persistence. The second thing is that, as we noted before launch, roughly a year is needed to reach optimal payer coverage. We will keep monitoring payer policies as they take shape, such as the criteria used for initial coverage, which may be tied to clinical trial eligibility. Those exclusions appear in the second box on the right side of slide 25, rather than in the indication statement, along with the way each payer characterizes response during reauthorization. And last, we should keep in mind that PK deficiency is an uncommon, long-term condition that is not well understood. Our work on disease education and on promoting accurate diagnosis remains essential to securing success over the long run. The commercial team is intensely focused on these efforts, since PK deficiency demands numerous interactions both to educate about the disease, building urgency, and to confirm an accurate diagnosis. These early launch wins and the positive experiences we are building with the wider PK deficiency community give us great encouragement. We have assembled a dedicated commercial organization with deep rare disease expertise that is entirely able to carry out our strategy, and we are thrilled and thankful for the difference we are making in the lives of PK deficiency patients. Crucially, what this launch shows us is that our commercial strategy, our knowledge base, and the relationships we are forming are positioning us well for success as we keep broadening the applicability of PYRUKYND to all eligible PK deficiency patients, and over a longer horizon to other genetically defined diseases. With that, I will hand things over to Jonathan to go through the second quarter financials.

Jonathan Biller

executive
#5

Appreciate that, Richa. You can find our financial results for the second quarter of 2022 in the press release that went out this morning, and I'll walk through the highlights. Additional detail will appear in the 10-Q we file later today. Let's move to slide 28. As Richa mentioned, PYRUKYND revenue in the second quarter came to $3.1 million. On top of that, during the quarter we recognized $2.5 million in revenue tied to an upfront payment for the licensing of intellectual property related to our Friedreich's Ataxia preclinical program, which was discontinued back in 2020. Cost of sales for the quarter totaled $435,000. Now on to operating expense. R&D for the second quarter was $74.5 million, which is $12.5 million higher than the second quarter of 2021. That year-over-year rise in R&D came mainly from growth in headcount and workforce related expenses, planned increases in activity for the PAH preclinical program, start-up costs tied to the AG-946 Phase 2a MDS study, greater spend on the AG-946 Phase 1 trial, and start-up costs for the PYRUKYND pivotal studies in sickle cell disease and pediatric PK deficiency. SG&A expenses came in at $28.3 million for the second quarter, a decrease of $1 million versus the second quarter of 2021. This decline in SG&A was driven primarily by the wrap-up of the reimbursable transition-related services we provided to Servier in connection with the sale of the oncology business, which finished in the first quarter of 2022. TIBSOVO royalty revenue, recorded under royalty income and gain on sale of oncology business on our income statement, was $2.7 million. We closed the quarter with cash, cash equivalents and marketable securities of roughly $1.1 billion. Given that cash balance, we believe we can carry out our current operating plan through major catalysts and reach cash flow positivity without having to raise additional equity. With that, operator, please open the line for questions.

Marc Frahm

analyst
#6

Yes. Thank you for fielding this question, and congratulations on the quarter. This one may be directed at Richa. Could you describe the sort of full-time situation you're observing among those 52 start forms that have arrived, compared with the 37 patients who are on drug? And how do you anticipate that trajectory will shift over the remainder of the year?

Richa Poddar

executive
#7

Yeah. Marc, I appreciate the question; so, as we mentioned, we feel encouraged by the trends we're observing concerning both placing patients on the drug and securing access to the drug as well. So, we anticipate those will convert over time. Right now it takes roughly four to eight for patients to begin therapy, since we are still moving through the medical exception process while payer policies have been developed. As we've noted previously, slow and steady is how we foresee this launch, including the second half. I believe two things are worth keeping in mind here. The patients continue titrating through their therapy; so, per our label, we have the six months assessment, at which the assessment of response will be conducted for the patient. And based on that, at least from our clinical perspective, we know it's roughly 40% to 45% of patients who are expected to respond. We had some patients drop-off. And then, as the payer policies and the authorization developed, we know more as well regarding what that second half looks like; so those are the two things just to take into consideration as we head into the to the second half, but we are very encouraged with this early launch trend in terms of both diversity of patients who are getting prescribed drugs as well as the breadth of prescribing across the country.

Marc Frahm

analyst
#8

All right, that's useful. Then, I realize the criteria process for the new authorization regimen is still quite early, yet regarding the initial feedback you're receiving about the reauthorization process, how tightly are you observing those plans follow the response criteria from the trial, versus being receptive to perhaps a wider reading of what constitutes a response?

Richa Poddar

executive
#9

So, I believe this really is a rare disease, correct? That is — so I think here's the discussion between the division and the plans, plus our ongoing engagement with the payers, which we have kept doing and will keep doing as those reauthorization and utilization management criteria take shape, is going to matter a great deal. So, those interactions so far have been favorable. Still too soon to say, like I mentioned, but it keeps moving in the direction we were hoping for.

Marc Frahm

analyst
#10

All right, thank you very much.

Analyst

analyst
#11

This is < > on the line, filling in for Greg. We appreciate you taking our questions, and congratulations on the quarter. I might just ask a follow-up about the patients receiving PYRUKYND. I'm curious, of those 37, what number represented newly added patients during this quarter? Also, what do you anticipate for NRx growth over the back half of the year? Which headwinds and tailwinds ought we to keep in mind? Then, second, regarding the Anemia ID diagnostic kit, I'd like to know whether the positivity rate depends on prevalence, or if other variables can push that positivity rate higher. And over the long run, where do you expect that rate to go? Thanks.

Richa Poddar

executive
#12

Absolutely, let me start with the Anemia ID question. We shared the positivity rate because we think it has reached a fairly stable level, and it’s been holding steady for some time now. Just to remind everyone, Anemia ID wasn’t created specifically for PK deficiency, correct? We built it around what physicians and healthcare professionals needed, along with what we understood was necessary to enhance diagnosis for hemolytic anemia overall. Okay, Anemia ID was created to look for hemolytic anemia when the cause isn't known, and to help doctors get a handle on the underlying expense tied to hemolytic anemia rather than something tied specifically to PK efficiencies. So right now, we have nothing telling us to expect the positivity rate for PKD in particular to move upward. That covers Anemia ID. As for your NRx versus TRx question, it's honestly too soon to say much. What matters, I think, is that growth has been slow and steady, which is what we expected, and patients are coming from a very broad range of demographics. What we're observing isn't limited to any particular category of patient receiving the drug. It spans different hemoglobin readings and various disease features that mirror the adult PKD population — that's a positive sign — and it's happening nationwide, which is likewise encouraging and matches what you'd anticipate. Since this is an uncommon, long-term condition that isn't clustered at specific specialty hubs, you'd naturally expect this pattern to follow the disease broadly. Once more, to reiterate what I mentioned before: during the back half, much of what we have — this marks our initial complete quarter, so things remain quite preliminary. We still need to find out what the six-month assessment shows regarding real-world efficacy, and pinning that down is going to require a substantial amount of time. In the clinical trial setting, though, the figure was 40% to 45%. On top of that, we need to watch how payer policies develop around reauthorization and utilization management criteria, since those will have an impact too. So our grasp of the trends has improved — we're looking at something closer to the complete picture instead of just two or three quarters — and things are heading in the right direction, which is a positive sign.

Analyst

analyst
#13

Great. Thank you.

Andrew Berens

analyst
#14

Hi. Congrats on how the launch is going, and thanks for the detail on the addressable market. I was curious whether you could also share some detail about which genotypes the PKD patients taking commercial PYRUKYND have? Then, a second one about the thalassemia opportunity. With Bristol having halted their program in that cohort, do you have any views on the transfusion independent opportunity?

Richa Poddar

executive
#15

Yeah; so, regarding genotype, just to remind everyone, right, you can get a PK deficiency diagnosis either through enzyme testing or through genetic testing. Therefore, we don't consistently have genetic testing results for all individuals taking PYRUKYND, though doctors aren't a factor we're encountering right now. As you remember from our prescribing information, it's quite expansive, which we owe to the efforts of the clinical and regulatory groups. Consequently, it's indicated for grown-up PKD sufferers. Every person aged 18 or above can presently receive PYRUKYND, and that matches what we see in our prescribing patterns. So that's encouraging. What we're hearing from doctors isn't that they'll restrict treatment to particular genotypes and withhold it from others. Based on what our data shows, that pattern simply isn't appearing. Now, on the thalassemia side of your question, which you brought up yourself — there are a few points worth making, and I'd also like Sara to weigh in from the clinical perspective. It's really quite encouraging that positive experiences with PKD are beginning to build up, since the very same group of physicians and healthcare professionals will be the ones evaluating thalassemia and writing prescriptions for thalassemia drugs. As they gain more experience and our familiarity with the drug grows, we'll be in a stronger position once we secure approval in thalassemia. The program we've built is intended to tackle alpha thalassemia along with both non-transfusion-dependent and transfusion-dependent forms. We recognize that luspatercept currently reaches just a modest share of thalassemia patients—specifically those with transfusion-dependent beta—and many individuals still don't respond to it. What's truly needed here is an easy-to-take pill form of treatment. Doctors have told us they see enormous worth in that, both in terms of how we've built the trial design and in the overall picture the data presents, which covers positive effects on a broad range of functional measures too. Across all three hemolytic anemias, the benefit shown in our proof-of-concept results holds steady, and we think that puts us in a really strong position. So what we're observing has us quite optimistic, though Sarah is better placed to speak further about the thalassemia clinical development plan.

Sarah Gheuens

executive
#16

Okay, thanks Richa. From where we sit in clinical development, we're still feeling good and staying on schedule with the thalassemia program; that recent decision doesn't change how we view this program or our odds of succeeding. There are a few reasons for that — we've always intended to provide the complete data package for the transfusion-dependent and non-regularly transfused groups, which Richa went over earlier. Beyond that, our mechanism of action works quite differently. Both therapies do raise hemoglobin, sure, but given how our mechanism differs and the results we've been collecting across various clinical programs — including beginning to observe signals of an effect on iron overload — we remain confident in our programs and keep advancing with the same likelihood of success.

Andrew Berens

analyst
#17

Excellent, thank you. Appreciate that. Perhaps one for Jackie regarding VOC. You folks aren’t thinking about buying GBT, are you? Or is that merely a joke? Thanks for accepting the question. I appreciate it.

Jackie Fouse

executive
#18

What if I just laugh at that?

Andrew Berens

analyst
#19

All right. All right.

Analyst

analyst
#20

I'm Jaclyn, sitting in for Mark at Oppenheimer. Congratulations on the quarter, and thank you for taking our question. Question one: what's the count of new scripts? What was the retention rate per month during 2Q? Also, have you observed any prescription abatement stemming from payer-related problems?

Jackie Fouse

executive
#21

Yes. I missed the beginning of what you asked, so perhaps I'll respond to the latter portion and then return to your initial question. So, I believe you were asking about abatement, possibly. So, once more, what's truly — we haven't observed patients who received a prescription for the drug being unwilling to undergo therapy. We've been — once therapy has been prescribed, we bring our patients into myAgios, our high-touch patient support program, which genuinely assists with getting patients to begin therapy and then remain on it. What we've observed anecdotally with a small number of patients is that certain patients are pushing back when they start therapy, while experiencing a life event such as a wedding or a holiday. So, they're waiting when it comes to halting their therapy, though at this early point we aren't seeing a. I'm not sure what your first question was, my apologies. So, if you wouldn't mind repeating it. I didn't quite catch it.

Analyst

analyst
#22

Yeah. So, what's the count on those new scripts? And for Q2, what did monthly retention come in at?

Jackie Fouse

executive
#23

Well, we haven't given exact figures on those new scripts, so to speak. What we've stated is this: 52 prescriptions are out there, and 37 of them have been filled. That covers patients who started during this quarter along with those carrying over from the quarter before.

Analyst

analyst
#24

Okay. Thank you; my next question concerns the RISE UP trial. Enrollment for the Phase 2 portion of RISE UP is set to finish by year-end. Might we anticipate a dose selection decision during the first half of 2023? Also, what initial data from the trial will be available — only safety and hemoglobin response, or might we also see some secondary endpoint data?

Sarah Gheuens

executive
#25

Hi, this is Sarah. You won't see data in the first quarter of 2023, since the trial — Phase 2 includes a 12-week follow-up period. Every patient has to complete that, go through safety follow-up, and then we must perform the database lock and review the data. That simply cannot occur in Q1. As for the data you'll see — obviously we're collecting more than just hemoglobin response and safety in that Phase 2, because we're going to gather all of the data, and I've outlined the secondary endpoints in our presentation. So we'll be analyzing all of the data to inform our go, no-go decisions for Phase 3, and there are pre-specified criteria for dose selection as well. We'll be very focused on moving from Phase 2 to Phase 3, but we will present the data we have at an upcoming medical conference when ready, which we hope will be more toward the end of the year.

Analyst

analyst
#26

Excellent. That is quite useful. Many thanks, and once more, congratulations on the quarter.

Sarah Gheuens

executive
#27

Thanks.

Analyst

analyst
#28

This is < > calling in for Salveen, and thank you for taking our question. Could you give us more detail on how PYRUKYND is launching in PKD? Will you keep pursuing the same strategies for finding patients? Or are you using different approaches to broaden patient identification? Also, among those who test positive with the Anemia ID test, what number actually go on to receive PYRUKYND treatment? And finally, regarding PKD and sickle cell, what's your view of the market opportunity — in particular, which patient group do you believe fits PYRUKYND best? Thank you.

Jackie Fouse

executive
#29

Yeah. So, maybe I'll begin with Anemia ID and then go backward from there; so first, I think it's really crucial to keep in mind that from a compliance standpoint, there's no way we can know which patient has been identified as a PKD patient, or which physician that patient belongs to; so it's really crucial that we keep driving disease awareness as well as achieving better diagnosis as time goes on. Anemia ID isn't designed specifically around pyruvate kinase deficiency. Instead, it was built to address what the community needs — assisting with differential diagnosis when a hemolytic anemia has an unknown etiology. That's the source of the test's value, and it's actively being used. Growth in this test keeps happening, driven by demand from the community and by use of the test in that differential diagnosis process, which lets them customize treatment for each patient based on which type of hemolytic anemia that patient has. And for at least one of those hemolytic anemias — pyruvate kinase deficiency — a treatment now exists. So that's really the key concept to keep in mind when you think about Anemia ID on its own. Turning to diagnosis — once again, I'd say it matters a great deal that pyruvate kinase deficiency is an uncommon, long-term illness, and you won't find it clustered within particular centers of excellence. Instead, it's spread across the whole country, with the bulk of care happening in community settings. We're focusing our work—keeping in mind what we know about how this disease operates—on boosting recognition of it, keeping up education regarding how much it weighs on patients, collaborating tightly with our physician partners so that whatever insights we gain get passed along to the wider community, and making sure we keep pushing for diagnoses. That push will matter at launch, yet it also casts a shadow over this therapeutic area, and the same holds for uncommon conditions. So we're observing gradual, consistent improvement when it comes to getting patients a diagnosis, and for those who qualify, getting them started on therapy, and that is going to remain our priority the whole way through. Then, turning to sickle cell, I'd like Sarah to speak directly about how the Phase 3 trial is designed, since that serves as a good bridge into how we're thinking about setting our product apart in that area too. Sarah, could you walk us through RISE UP?

Sarah Gheuens

executive
#30

Absolutely. So, the Phase 3 — RISE UP, that is, is a trial design that's operationally seamless, starting from the Phase 2 portion we were just talking about and then continuing into Phase 3. What's operationally seamless about it actually gives us quite a bit of flexibility, since it lets us activate sites early and have them prepared to enroll as fast as possible, while at the same time still letting us read out the Phase 2 data and make whatever adjustments might be needed without affecting the statistical or regulatory elements of the trial; and then for the Phase 3 portion, it's designed around two primary endpoints, the hemoglobin response and the analyzed sickle cell pain crisis endpoint, which if either one, or both, permitted us to proceed to testing of secondary endpoints, which provides the totality of data we'd need in order to make a meaningful story for patients and physicians and regulators. In that sense it's very similar to our other trials, correct? What's beautiful about the RISE UP trial is that it does let us essentially address anemia and address VOC, both of which matter greatly in the context of sickle cell disease, and our hope is that, that data lets us bring forward a treatment for sickle cell disease as a disease in its entirety.

Jackie Fouse

executive
#31

Also, one more point to build on what Sarah mentioned — we created these clinical trials with differentiation in mind, guided by feedback the community gave us. Physicians and patients within the wider sickle cell community helped us grasp what's needed, and the study was built to match. On the commercial side, any choice there hinges on the full picture the data provides before we settle on anything, though we're putting the study together so that we're positioned to succeed.

Analyst

analyst
#32

Thanks.

Danielle Brill

analyst
#33

Hello, and good morning. I really appreciate you taking the question. I suppose this is a follow-up to a few earlier ones — perhaps I'll frame it differently. With what you're expecting around possible discontinuations when the six-month point arrives, I'm curious whether a bolus of patients was added in 1Q that could affect growth in 3Q. If you could give a bit more color on how we ought to think about sequential revenue growth, that would be terrific. Thank you.

Richa Poddar

executive
#34

As we've mentioned, correct, 52 patients have been prescribed PYRUKYND. Filling the prescription takes four to eight weeks. Right now 37 are on therapy, and that number covers those who have started therapy along with those with refills. So they're titrating through the drug. On that, we won't go into further specifics at this point. Once again, this marks our first full quarter of launch, and much more remains to be learned; we're already learning plenty about which messages work and which don't, they're observing how physicians and patients respond to our strategy, and we keep holding and keep learning. That will be an ongoing process; so it's very early to say anything more.

Jackie Fouse

executive
#35

Also, I believe it's worth reminding everyone that during Q1 there wasn't any bolus of patients. In fact, most patients came on board in Q2. So what I think we're beginning to observe is that we've consistently described this as a gradual, steady launch and a matter of building the market, and the outstanding efforts of our commercial team are beginning to bear fruit as we gain traction through disease awareness, diagnosis, and getting patients started. I expect this will remain a steady progression, but there was no bolus back in Q1.

Danielle Brill

analyst
#36

Got it. Thanks.

Analyst

analyst
#37

This is Mary, filling in for Greg. We appreciate you taking our question. You brought up that knowledge around PKD, along with diagnostics, might grow alongside familiarity with a therapy like PYRUKYND. Have you actually been observing that kind of uptick? In what way do you intend to measure it? And how much time do you figure that growth would need? Thank you.

Richa Poddar

executive
#38

So, this is — so when you consider advantage, right, again, I'd say it's an uncommon condition, an ultra-rare one, persistent, and it isn't centered in the centers of excellence; so a great deal of work and time will be required before we can show any particular patterns regarding where disease awareness stands. What I'd point to is a forward-looking signal we've discussed with all of you today — on this call. First, we're observing a wide range of PKD patients — adult PKD patients beginning therapy; we're seeing this distributed across the nation. That tells us our awareness initiatives are paying off, and we can get doctors nationwide, get specialists nationwide, plus patients, started on therapy and build awareness with them; on top of that, we're also noticing slower start growth on our Anemia ID kits, which is our — a primary method we use to assist with diagnosing hemolytic anemia of unknown etiology, which, again, is built with the aim of helping enhance diagnosis as time goes on. So those two factors will be beneficial over the long run. As a reminder, 30% of — we currently believe 30% of PKD patients receive a diagnosis, and we anticipate that figure reaching roughly 70% at peak, requiring around five to seven years to arrive there; so, because of how this disease behaves and the reality that it isn't concentrated, it's going to take time — hence, you see any figure we could sensibly speak to; but the trends are heading the right way.

Analyst

analyst
#39

Great. Thank you.

Jackie Fouse

executive
#40

Thank you, operator, and thanks to each of you for your questions this morning. As I always do, I want to close by expressing appreciation to my Agios colleagues for their commitment and their passion for changing patients' lives. I'd also like to thank every patient, caregiver, and physician who works alongside us in so many capacities, particularly those enrolled in our clinical trials across indications. The bonds we share with our stakeholders, along with our collection efforts, drive the innovation and impact we continue to deliver for people living with genetically defined diseases. I also need to pause for just a moment and mark this occasion, since it's my final quarterly results call for Agios in the CEO role, and once more convey my gratitude to our incredible team for all that they do. It's wonderful to have such a strong quarter with our first full quarter of launch for PYRUKYND in PKD in adults in the U.S; and there are so many remarkable aspects of this moment. And I'm extremely thankful for Brian coming aboard, as I see this as something that adds to Agios, with him arriving as the new CEO bringing a fantastic skill set to our team, and with me moving into the position of Chair of the Board, still part of the team. So, with that, I look forward to your continued support. Thank you for the support you've given in the past, and here's to a wonderful future and many strong quarters ahead for Agios. Thanks so much for being with us today. You may now disconnect.

Operator

operator
#41

This concludes today's conference call. Thank you for participating. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.